🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Beth-Ann Coller

Merck & Co., Inc., Rahway, NJ, USA (United States)

ORCID: 0000-0001-6006-1073

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial”.

Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial

American Journal of Tropical Medicine and Hygiene(2020)10.4269/ajtmh.20-0042

N/A

0.895DataRank · unranked

27 citations

Kristen K. Pierce, Beth D. Kirkpatrick, Palmtama L. Grier, Beulah P. Sabundayo, Helen He +11 more

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Clinical Infectious Diseases(2023)10.1093/cid/ciad693

N/A

0.671DataRank · unranked

16 citations

Ken Liu, Édouard Lhomme, Julie Blie, John McCullough, Matthew Onorato +90 more

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

Trials(2021)10.1186/s13063-021-05035-9

N/A

0.630DataRank · unranked

18 citations

Édouard Lhomme, Mark Kieh, Abdoul Habib Béavogui, Stephen B. Kennedy, Seydou Doumbia +91 more

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Nature Communications(2024)10.1038/s41467-024-51453-z

N/A

0.596DataRank · unranked

19 citations

Édouard Lhomme, Mélanie Huchon, Emile Foucat, Marion Bérerd-Camara, Lydia Guillaumat +94 more

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Emerging Microbes & Infections(2024)10.1080/22221751.2024.2432353

N/A

0.251DataRank · unranked

4 citations

Marie Alexandre, Mélanie Prague, Abdoul Habib Béavogui, Seydou Doumbia, Mark Kieh +94 more